Last Updated : April 29, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area Sort descending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Erbitux | Cetuximab | Metastatic Colorectal Cancer | Do not reimburse | Complete | ||
| Stivarga (CRC) | Regorafenib | Metastatic Colorectal Cancer | Do not reimburse | Complete | ||
| Stivarga Resubmission (CRC) | Regorafenib | Metastatic Colorectal Cancer | Do not reimburse | Complete | ||
| Zaltrap | Aflibercept | Metastatic Colorectal Cancer | Do not reimburse | Complete | ||
| TBC | fruquintinib | Metastatic colorectal cancer (mCRC) | Pending | |||
| Cyramza | Ramucirumab | Metastatic Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Opdivo | Nivolumab | Metastatic Hepatocellular Carcinoma (HCC) | Do not reimburse | Complete | ||
| Enhertu | trastuzumab deruxtecan | Metastatic HER2 positive breast cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Yondelis | Trabectedin | Metastatic Liposarcoma or Leiomyosarcoma | Do not reimburse | Complete | ||
| Cotellic | Cobimetinib | Metastatic melanoma | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : April 29, 2024